International Journal of Hematology

DOI: 10.1007/s12185-019-02644-8 Pages: 711-717

Outcome of allogeneic hematopoietic stem cell transplantation in adult patients with hepatitis-associated aplastic anemia

1. Keio University School of Medicine, Division of Hematology, Department of Medicine

2. Tohoku University Hospital, Department of Hematology and Rheumatology

3. Japanese Red Cross Nagoya First Hospital, Department of Hematology

4. Meitetsu Hospital, Department of Hematology

5. Kita-Fukushima Medical Center, Division of Hematology

6. Jichi Medical University Saitama Medical Center, Division of Hematology

7. The University of Tokyo Hospital, Department of Cell Therapy and Transplantation Medicine

8. Kanagawa Cancer Center, Department of Hematology

9. Kindai University Faculty of Medicine, Division of Hematology and Rheumatology, Department of Internal Medicine

10. Nagasaki University Hospital, Department of Hematology, Atomic Bomb Disease and Hibakusha Medicine Unit

11. National Cancer Center Hospital, Hematopoietic Stem Cell Transplantation Division

12. Hiroshima University, Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine

13. Japanese Data Center for Hematopoietic Cell Transplantation

14. Nagoya University Graduate School of Medicine, Department of Healthcare Administration

15. Kanazawa University Hospital, Division of Transfusion Medicine

Correspondence to:
Takehiko Mori
Tel: +81-3-3353-1211



Outcomes of allogeneic hematopoietic stem cell transplantation (HSCT) for hepatitis-associated aplastic anemia have not been fully evaluated. In the present study, the outcomes of 37 adult patients with hepatitis-associated aplastic anemia who underwent allogeneic HSCT were retrospectively analyzed using the registry database of Japan Society for Hematopoietic Cell Transplantation. The median age of the patients was 24 years (range, 16–61). The median period between diagnosis of hepatitis-associated aplastic anemia and HSCT was 6.0 months (range, 0.5–430.8). Stem cell sources were bone marrow (N = 19) or peripheral blood stem cells (N = 5) from an HLA-identical sibling or bone marrow (N = 11) and cord blood (N = 2) from an unrelated donor. The majority of conditioning regimens were fludarabine-based or high-dose cyclophosphamide-based. In all but 2 cases of early death, neutrophil engraftment was achieved. At the time of analysis, 32 patients were alive, with a median follow-up of 54.1 months. Five-year overall and failure-free survival rates were 86.0% (95% CI, 69.4–93.9%) and 75.0% (95% CI, 57.4–86.2%), respectively. Despite the heterogeneity in transplant procedures in a small number of patients, these results suggest that allogeneic HSCT is safe for use in hepatitis-associated aplastic anemia with a low rate of transplant-related mortality.

To access the full text, please Sign in

If you have institutional access, please click here

Share the Knowledge